Cited by 189Cancer, Hypoxia, and MetabolismCancer, Lipids, and MetabolismChromatin Remodeling and Cancer

The emerging role of fumarate as an oncometabolite

Open access
Yang, Ming, Soga, Tomoyoshi, Pollard, Patrick J., Adam, Julie·2012·Frontiers in Oncology

Abstract

The drive to understand how altered cellular metabolism and cancer are linked has caused a paradigm shift in the focus of cancer research. The discovery of a mutated metabolic enzyme, isocitrate dehydrogenase 1, that leads to accumulation of the oncometabolite 2-hydroxyglutarate, provided significant direct evidence that dysfunctional metabolism plays an important role in oncogenesis. Striking parallels exist with the Krebs cycle enzyme fumarate hydratase (FH), a tumor suppressor, whose mutation is associated with the development of leiomyomata, renal cysts, and tumors. Loss of FH enzymatic activity results in accumulation of intracellular fumarate which has been proposed to act as a competitive inhibitor of 2-oxoglutarate-dependent oxygenases including the hypoxia-inducible factor (HIF) hydroxylases, thus activating oncogenic HIF pathways. Interestingly, our studies have questioned the role of HIF and have highlighted other candidate mechanisms, in particular the non-enzymatic modification of cysteine residues (succination) that could lead to disruption or loss of protein functions, dysfunctional cell metabolism and cell signaling. Here, we discuss the evidence for proposing fumarate as an onco-metabolite.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2012.00085

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A third 2HGA arises from germline mutations in SLC25A1, in which both enantiomers accumulate.

    “A third 2HGA that arises from germline mutations in the mitochondrial citrate carrier SLC25A1, in which both enantiomers accumulate, has also been discovered.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 63 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yang, M., Soga, T., Pollard, P. J., & Adam, J.
Affiliations
  • University of Oxford (GB)
  • Keio University (JP)
Corresponding author
Pollard, Patrick J.
Venue
Frontiers in Oncology
Published
2012
Volume
2
Pages
85-85
ISSN
2234-943X (ISSN-L)
OpenAlex
W2167537549
Cited by
189
References
63
Citations by year
2026: 8 · 2025: 13 · 2024: 13 · 2023: 12 · 2022: 24 · 2021: 18 · 2020: 18 · 2019: 18 · 2018: 16 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 10 · 2013: 9 · 2012: 1
FWCI
3.08
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Wellcome Trust
  • Cancer Research UK
  • Keio University
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
fumarate, oncometabolites, fumarate hydratase, IDH1, 2-hydroxyglutarate, 2-oxoglutarate-dependent dioxygenase, cysteine modification, cancer metabolism, tumor suppressor, TCA cycle

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review